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Abstract In the diagnosis of atherosclerosis, detailed evaluation of biomarkers
related to its lesion formation is desired for estimation of its progression rate. In our
previous proteomic studies of atherosclerosis mice, the protein level of
thrombospondin-4 (TSP4) in the aorta, but not in plasma, elevated relatively with
atherosclerotic plaque formation. Therefore, we supposed that TSP4 would be a
potential biomarker for diagnostic imaging of atherosclerotic progression. Immu-
noglobulin G (IgG) has been widely used as a basic molecule of imaging probes
providing images specific to their target biomolecules, owing to the antigen-
antibody reaction. Therefore, we first developed anti-TSP4 monoclonal IgG
radiolabeled with 99mTc (99mTc-TSP4-mAb). 99mTc-TSP4-mAb showed higher
accumulation in atherosclerotic aortas of apoE/ mice (atherosclerotic model
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mice); however, we found that the non-targeted monoclonal IgG radiolabeled with
99mTc also showed similar distribution in atherosclerotic aortas of apoE/ mice.
IgG has also known to accumulate nonspecifically in the immunological disease
such as inflammatory arthritis. However, the accumulation mechanism of IgG has
still been unclear in detail. In this chapter, we would like to introduce recent topics
on atherosclerotic imaging, focused on our work exploring the accumulation
mechanisms of IgG in atherosclerotic lesions, and elucidating the usefulness of
radiolabeled IgG images in the diagnosis of atherosclerosis.
Keywords Atherosclerosis • Immunoglobulin G • Polarized macrophage
11.1 Introduction
Rupture of vulnerable plaques and the subsequent thrombogenesis induce ischemic
diseases such as cerebral and myocardial infarction [1]. Therefore, it is necessary
to detect vulnerable lesions precisely for the diagnosis of such diseases. Various
biomolecules are expressed or activated as atherosclerosis progresses. Thus, the
detection and imaging of such biomolecules would make possible the determina-
tion of the progression of atherosclerosis in detail. In our previous proteomic
studies of atherosclerotic model mice [2], the relative thrombospondin-4 (TSP4)
levels of atherosclerotic model mice/normal mice in the aorta, but not in plasma,
increased with the atherosclerotic plaque formation. TSP4 belongs to the
thrombospondin families and has been reported to play some roles such as pro-
motion of proliferation of smooth muscle cells and adhesion and migration of
neutrophils [3]. It has also been reported that apoE and TSP4 double knockout
mice showed fewer atherosclerotic lesions than the atherosclerosis apoE knockout
mice, which suggests that TSP4 has a crucial role in the progression of atheroscle-
rotic lesions [4]. Therefore, we supposed that TSP4 would be a potential biomarker
for diagnostic imaging of atherosclerotic progression. Immunoglobulin G (IgG) is
widely used particularly for the target-specific imaging of cancer, because it pro-
vides images specific to their target biomolecules owing to the antigen-antibody
reaction [5]. Thus, we first developed an IgG-based TSP4 targeting SPECT
imaging probe (99mTc-TSP4-mAb). 99mTc-TSP4-mAb accumulated in the athero-
sclerotic lesions of apoE/ mouse aortas. However, 99mTc-NC-mAb, which was
composed of non-targeting IgG, also accumulated highly in the atherosclerotic
lesions similar to 99mTc-TSP4-mAb. IgG itself is known to be delivered to athero-
sclerotic lesions nonspecifically, but the detailed mechanism of the accumulation
is still unknown [6].
In this report, we would like to introduce our above-mentioned work in which
we explored the accumulation mechanisms of IgG in atherosclerotic lesions and
elucidated the usefulness of radiolabeled IgG imaging in the diagnosis of
atherosclerosis.
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11.2 Materials and Methods
11.2.1 Materials
All chemicals used in this study were commercially available and of the highest
purity. HYNIC-N-hydroxysuccinimide was prepared as previously reported
[7]. 99mTc-pertechnetate was purchased from Nihon Medi-Physics Co., Ltd.
(Tokyo, Japan). As a TSP4-targeting monoclonal antibody, we used anti-
thrombospondin-4 mouse IgG2b (Clone #276523, R&D Systems, Abingdon, UK).
As for the negative control non-targeted mouse IgG, we chose mouse IgG2b, a
kappa monoclonal [MG2b-57] isotype control (Abcam, Cambridge, UK) whose
immunogen is trinitrophenol + keyhole-limpet hemocyanin (KLH).
11.2.2 Preparation of Radiolabeled IgG
Anti-TSP4 monoclonal IgG (TSP4-mAb) or non-targeting IgG (NC-mAb) was
radiolabeled with 99mTc after derivatization with 6-hydrazinonicotinic acid
(HYNIC), as previously reported (Fig. 11.1) [8]. In brief, to HYNIC-N-hydroxysuc-
cinimide (8.25 μg) in N,N-dimethylformamide (8.25 μl), TSP4-mAb or NC-mAb
solution in 0.16 M borate buffer (pH 8.0) (250 μl, 2 mg/ml) was added, and the
Fig. 11.1 Scheme of 99mTc-TSP4-mAb or 99mTc-NC-mAb preparation
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mixture was incubated at room temperature for 2 h. The mixture was purified
by size-exclusion filtration using a diafiltration membrane (Amicon Ultra
4 [cutoff molecular weight, 30,000]; Millipore Co., Billerica, MA). 99mTc-
(tricine)2(740 MBq/ml, 300 μl) was prepared by the method of Larsen et al.
[9]. It was added to the purified solution of HYNIC-TSP4-mAb or NC-mAb
solution in 10 mM citrate buffer (pH 5.2) (30 μl, 1 mg/ml), and the mixture was
incubated at room temperature for 1 h. The mixture was then purified on a Sephadex
G-25 column (PD-10, GE Healthcare, Buckinghamshire, UK) equilibrated with
0.1 M PBS (pH7.4) to obtain 99mTc-TSP4-mAb or 99mTc-NC-mAb. The radio-
chemical purity of 99mTc-TSP4-mAb or 99mTc-NC-mAb was measured by size-
exclusion filtration of the PD-10 column and size-exclusion high-performance
liquid chromatography (HPLC). The stability of 99mTc-TSP4-mAb or 99mTc-NC-
mAb in plasma was evaluated by the method described below. First, the probes
(99mTc-TSP4-mAb, 27.7 MBq/ml; 99mTc-NC-mAb, 34.9 MBq/ml; 50 μl) were
incubated with the plasma derived from C57BL/6 (male, 30 weeks) for 24 h, and
then the mixture was analyzed by size-exclusion filtration of the PD-10 column.
11.2.3 Animal Study
Animal care and all experimental procedures were performed with the approval of
the animal care committee of Hokkaido University. Studies were performed using
male C57BL/6J apoE/ mice obtained from the Taconic Gnotobiotic Center
(Germantown, NY, USA) and C57BL/6J mice as the wild-type (WT) mice obtained
from Charles River Laboratories Japan, Inc. (Yokohama, Japan). The animals were
kept in a temperature-controlled facility of the laboratory of animal experiments of
Hokkaido University on a 12-h light cycle with free access to food and water. After
5 weeks of age, the apoE/ mice were maintained on a high-fat diet (21 % fat,
0.15 % cholesterol, without cholate; purchased from Oriental Yeast Ltd., Tokyo,
Japan). At 35 weeks of age, the animals (n¼ 4/group) were anesthetized with
pentobarbital (0.025 mg/kg body weight, intraperitoneally). 99mTc-TSP4-mAb
(200–592 kBq/mouse) or 99mTc-NC-mAb (481–962 kBq/mouse) was intravenously
injected to each animal. Twenty-four hours after the injection, the animals were
euthanized under deep pentobarbital anesthesia, and aortas were fixed by cardiac
perfusion with cold 0.1 M phosphate-buffered saline (pH 7.4) followed by a cold
fixative [4 % paraformaldehyde, 0.1 M phosphate-buffered solution (pH 7.4)]. Each
excised aorta was cut and placed onto glass slides. The dissected aortic root of each
mouse was embedded in Tissue-Tek medium (Sakura Finetechnical Co., Ltd.,
Tokyo, Japan) and frozen in isopentane/dry ice. Serial cross sections of 10-μm
(for autoradiographic study) and 5-μm (for immunohistochemistrical analysis)
thickness were immediately cut and thaw-mounted on glass slides.
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11.2.3.1 Autoradiography (ARG) Study
The excised and cut aortas on glass slides were exposed to phosphor imaging plates
(Fuji Imaging Plate BAS-UR, Fujifilm, Tokyo, Japan) for 12 h, together with a set
of calibrated standards. The autoradiographic images were acquired using a com-
puterized imaging analysis system (Fuji bio-imaging analyzer FLA7000). The
acquired data was analyzed using MultiGauge version 3.2 (Fujifilm).
11.2.4 Histochemical Study
Movat’s pentachrome staining of serial aortic root sections was performed
[10]. Immunohistochemical staining of the serial sections with a mouse
macrophage-specific antibody (Mac-2, clone m3/38, Cedarlane, Ontario, Canada)
was performed in accordance with a previously reported immunohistochemical
procedure [11]. The TSP4 immunohistochemical staining of the serial sections
was performed as shown below. At first, endogenous peroxidase activity was
blocked for 10 min with 3 % hydrogen peroxide after rehydration. Slides were
then incubated with anti-thrombospondin-4 mouse IgG2b (Clone #276523, R&D
Systems) overnight at 4 C, followed by incubation with a peroxidase-labeled
amino acid polymer-conjugated goat anti-mouse F(ab0)2 fragment of IgG (Histofine
Mouse Stain kit, Nichirei, Tokyo, Japan) for 30 min at room temperature. The
bound antibody complex was then visualized by incubation with 3,3-
0-diaminobenzidine tetrahydrochloride. The images of the staining shown above
were captured under a microscope (Biozero BZ-8000; Keyence Co., Osaka, Japan).
11.3 Results
11.3.1 Probe Preparation
99mTc-TSP4-mAb or 99mTc-NC-mAb was obtained with a radiochemical yield of
17.6 3.8 % or 31.8 6.8 % (n¼ 3) and with the radiochemical purity of
99.5 0.1 % or 99.2 0.5 % (n¼ 3). The stability of 99mTc-TSP4-mAb or
99mTc-NC-mAb in the mouse plasma was over 90 % for 24-hour incubation.
11.3.2 In Vivo Study
The distributions of 99mTc-TSP4-mAb in apoE/ mice and wild-type (WT) mice
at 24 h after administration are shown in Table 11.1. The 99mTc-TSP4-mAb
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accumulation levels in the aortas of apoE/ mice were significantly higher than
those in WT mice (5.3 1.1 vs. 2.4 0.3 %ID/g, p< 0.05), whereas the radioac-
tivities in other organs were not significantly different between apoE/ mice and
wild mice. On the other hand, the 99mTc-NC-mAb accumulation levels in the aortas
of apoE/ mice were also significantly higher than those of WT mice (5.1 1.4
vs. 2.8 0.5 %ID/g, p< 0.05), whereas the radioactivities in other organs were not
different between apoE/ mice and wild-type mice.
The ARG images of the apoE/ aortas injected with 99mTc-TSP4-mAb showed
heterogeneous distribution of the radioactivity where the plaque formation was
observed in the bright field (Fig. 11.2). The radioactive distribution in the aortic
roots of apoE/ mice injected with 99mTc-TSP4-mAb measured by ARG was
inside of the atherosclerotic plaque lesions and coincided with the Mac-2-positive
areas (Fig. 11.3). These results suggest that 99mTc-TSP4-mAb accumulated in the




(WT) mice 24 h after
administration
apoE/ WT
Aorta 5.3 1.1 2.4 0.3
Heart 1.8 0.3 1.5 0.2
Lung 1.7 1.4 1.9 1.6
Liver 5.5 1.8 5.9 1.3
Kidney 2.5 0.2 2.3 0.3
Stomach 1.8 0.5 1.1 0.2
Small intestine 1.3 0.2 1.5 0.2
Large intestine 3.8 1.9 2.5 0.3
Pancreas 0.8 0.2 0.7 0.1
Spleen 7.5 1.2 6.7 0.8
Brain 0.1 0.1 0.1 0.0
Muscle 0.5 0.2 0.6 0.1
Blood 17.2 2.1 17.2 1.5
Fig. 11.2 ARG images (left) and bright field images (right) of the excised aortas of apoE/
mouse (upper) and of wild-type (WT) mouse (lower) 24 h after administration of 99mTc-TSP-mAb
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11.3.3 Discussion
In this study, we observed that 99mTc-TSP4-mAb accumulated in the atheroscle-
rotic lesions of apoE/ mouse aortas. However, 99mTc-NC-mAb, which was
composed of non-targeting IgG, also accumulated highly in the atherosclerotic
lesions similar to 99mTc-TSP4-mAb (Fig. 11.2). Moreover, the 99mTc-TSP4-mAb
accumulation area coincided with the Mac-2-positive areas in the plaques in aortic
root (Fig. 11.3), which suggests that IgG itself was delivered and accumulated in
atherosclerotic lesions, especially macrophage infiltration areas.
Previously, various types of polarized macrophage were identified and reported
[12]. Among the polarized macrophages, pro-inflammatory M1-polarized macro-
phages were reported to be abundant in lipids and to localize in areas that are
distinct from those in which anti-inflammatory M2-polarized macrophages (which
are also called alternatively activated macrophages) localize in human plaques
[13]. Although the origin of M1 and polarized macrophages and how polarized
macrophages are involved in the progression of atherosclerotic plaques are still
being unclarified, polarized macrophages would have a critical role in the devel-
opment of atherosclerotic plaques [14]. Therefore, we examined the correlation of
the macrophages, especially polarized macrophages, with IgG accumulation. In our
preliminary in vitro study, M1-polarized macrophages showed a higher uptake of
99mTc-NC-mAb than M2-polarized and non-polarized M0 macrophages [15]. To
clarify the mechanism of 99mTc-NC-mAb accumulation in M1-polarized macro-
phages, we next focus on the expression levels of Fcγ receptors. Fcγ receptors
recognize the Fc region of IgG and play a role in the activation of immune systems
[16]. Furthermore, it has been reported that deficiency of Fcγ receptors induces
Fig. 11.3 ARG images, Movat’s pentachrome staining, TSP4 immunohistochemical staining, and
Mac-2 immunohistochemical staining of the aortic roots of apoE/ mouse (upper) and wild-type
(WT) (lower) mouse 24 h after administration of 99mTc-TSP4-mAb
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protection against atherosclerosis in apoE/ mice [17]. Indeed, the expression
level of some subtypes of Fcγ receptors was higher in M1-polarized macrophages
than those in M2-polarized or non-polarized M0 macrophages in our unreported
in vitro study. We also performed a cellular uptake study under the Fcγ receptor’s
inhibition and found that the accumulation of 99mTc-NC-mAb in M1-polarized
macrophages was significantly suppressed by the pretreatment with an anti-Fcγ
receptor antibody. These findings suggest that IgG itself is accumulated in
M1-polarized macrophages via Fcγ receptors in the atherosclerotic plaques.
During the course of atherosclerotic progression, various biomolecules are
expressed or activated. Thus, various PET/SPECT imaging probes targeting bio-
molecules related to the progression of atherosclerosis have been developed
[18]. Among them, some probes are developed with based on monoclonal IgG
and have been evaluated in animal models such as mouse and rabbit [19, 20]. In
those studies, xenogeneic antibodies were used, whose nonspecific accumulation in
atherosclerotic lesions was not taken into consideration. However, considering that
the probes will be used clinically, the IgG used as a basic component of probes
should be humanized, and it would be necessary to note its nonspecific accumula-
tion as we have seen in this study.
Radiolabeled IgG has been widely applied to the diagnosis of inflammatory
diseases such as rheumatoid arthritis and infections, although the mechanism of its
accumulation is still unclarified [21]. Our preliminary study is the first to show that
pro-inflammatory M1-polarized macrophages contribute to the accumulation of
radiolabeled IgG, which is in agreement with the conventional use of such IgG as
mentioned above.
In the nuclear imaging for diagnosis of atherosclerosis, 18-fluoro-deoxyglucose
(18F-FDG) has been widely used [22]. 18F-FDG is reported to accumulate in
macrophages, particularly M1-polarized macrophages in atherosclerotic lesions
[23], which is similar to radiolabeled IgG behavior. Therefore, radiolabeled IgG
would provide information similarly to 18F-FDG in the diagnosis of atherosclerosis.
In this study, we found that IgG itself can be potentially used for the visualiza-
tion of atherosclerotic plaques, especially atherosclerotic lesions in active inflam-
mation independent of its target biomolecules. However, we also observed the high
retention of radioactivities in blood 24 h after administration of 99mTc-TSP4-mAb
(apoE/, 17.2 2.1 %ID/g; WT, 17.2 1.5 %ID/g), which were about three times
higher than those in aortas. This may be because that IgG has a high molecular
weight (about 150 kDa), which leads to a low rate of clearance from blood. To
overcome this problem, the molecular weight of IgG should be decreased with its
affinity to Fcγ receptors maintained. That is, an Fc fragment (about 50 kDa)
obtained from IgG would be a suitable basic compound for atherosclerotic imaging.
We are now developing an Fc fragment-based probe and evaluating to determine
whether this probe can be used to visualize the inflammatory active areas of
atherosclerotic lesions.
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